Lifelong Learning: Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer€™s Dementia in Individuals With Previous Depression-View Article

View Article

Pdf Summary

This study investigated the impact of selective serotonin reuptake inhibitor (SSRI) treatment on the risk of conversion from mild cognitive impairment (MCI) to Alzheimer's dementia in individuals with a previous history of depression. The authors evaluated data from 755 currently nondepressed participants with a diagnosis of MCI from the Alzheimer's Disease Neuroimaging Initiative cohort. The results showed that long-term SSRI treatment (over 4 years) was associated with a delayed progression to Alzheimer's dementia by approximately 3 years compared to short-term SSRI treatment, treatment with other antidepressants, or no treatment. However, there were no differences in cerebrospinal fluid biomarker levels between treatment groups. These findings suggest that long-term SSRI treatment may delay the progression from MCI to Alzheimer's dementia in individuals with a previous history of depression. Further studies are needed to validate these findings and investigate the underlying mechanisms.

Keywords

SSRI treatment

risk

conversion

MCI

Alzheimer's dementia

depression

long-term treatment

antidepressants

progression

findings